<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820556</url>
  </required_header>
  <id_info>
    <org_study_id>3162021</org_study_id>
    <nct_id>NCT04820556</nct_id>
  </id_info>
  <brief_title>Gut Microbiota in Chronic Noncommunicable Diseases</brief_title>
  <official_title>The Development of Preventive Methods for Chronic Noncommunicable Diseases Based on Modulation of Gut Microbiota Composition and Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Medical Research Center for Therapy and Preventive Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Strategic Planning and Management of Biomedical Health Risks of the Federal Biomedical Agency</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Medical Research Center for Therapy and Preventive Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is an observational study in patients with chronic noncommunicable diseases (i.e.&#xD;
      cardiovascular diseases, diabetes mellitus, non-alcoholic fatty liver disease, chronic&#xD;
      obstructive pulmonary disease and asthma ) and control group with no signs of these&#xD;
      conditions. The study has a prospective part planned for 2021 and a retrospective part which&#xD;
      includes the patients enrolled between 2018-2020. The aim of the study is to investigate gut&#xD;
      microbiota composition, its metabolites, levels of inflammatory and other markers of the&#xD;
      disease in prospective groups (arterial hypertension, type 2 diabetes mellitus, chronic&#xD;
      obstructive pulmonary disease, asthma, non-alcoholic fatty liver disease and control&#xD;
      patients) as well as in retrospective groups (chronic heart failure with preserved and&#xD;
      reduced ejection fraction, obstructive atherosclerosis of any vascular bed, arterial&#xD;
      hypertension, type 2 diabetes mellitus, chronic obstructive pulmonary disease, asthma,&#xD;
      non-alcoholic fatty liver disease, and control patients). Also we are planning to investigate&#xD;
      the association between gut microbiota composition and its metabolites, levels of&#xD;
      inflammatory and other markers of the disease in retrospective and prospective groups.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Significant (p&lt;0,05) correlation (r&gt;0,5) between abundance of Faecalibacterium genus and concentration of lipopolysaccharide</measure>
    <time_frame>on enrollment</time_frame>
  </primary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">1080</enrollment>
  <condition>Arterial Hypertension</condition>
  <condition>Atherosclerosis Occlusive Disease</condition>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Obstructive Pulmonary Disease</condition>
  <condition>Asthma</condition>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Arterial hypertension</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Atherosclerosis occlusive disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart failure with preserved ejection fraction</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart failure with reduced ejection fraction</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes mellitus, type 2</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic obstructive pulmonary disease and asthma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonalcoholic fatty liver disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, stool samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic noncommunicable diseases including cardiovascular diseases, type 2&#xD;
        diabetes mellitus, nonalcoholic fatty liver disease, chronic obstructive pulmonary disease,&#xD;
        asthma and control group&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Criteria for groups with arterial hypertension, chronic obstructive pulmonary disease&#xD;
        (COPD), asthma, type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD) (both&#xD;
        prospective and retrospective)&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
        All mentioned groups:&#xD;
&#xD;
          -  Men and women aged ≥ 18 and &lt;80&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
        Group of arterial hypertention (inclusion criteria):&#xD;
&#xD;
          1. No current treatment of hypertension&#xD;
&#xD;
          2. Systolic blood pressure &lt;180 mm Hg and diastolic blood pressure &lt;110 mm Hg&#xD;
&#xD;
          3. No clinical signs of other cardiovascular diseases&#xD;
&#xD;
        Group of COPD and asthma (inclusion criteria)&#xD;
&#xD;
          1. Medical records, confirming COPD or asthma&#xD;
&#xD;
          2. Regular stable treatment of COPD, asthma or any chronic disease for ≥ 4 weeks before&#xD;
             the enrollment. If inhaled corticosteroids are being used, regular treatment is&#xD;
             required for ≥12 weeks.&#xD;
&#xD;
          3. Absence of acute exacerbations of COPD, asthma or any concomitant diseases 4 weeks&#xD;
             before the enrollment&#xD;
&#xD;
          4. No use of genetically engineered biological drugs&#xD;
&#xD;
          5. For patients with COPD after inhalation of salbutamol (400 mcg) the ratio FEV1/FVC is&#xD;
             less than 0,70&#xD;
&#xD;
        Group of type 2 diabetes mellitus (inclusion criteria)&#xD;
&#xD;
          1. Confirmed type 2 diabetes mellitus&#xD;
&#xD;
          2. Stable glucose lowering treatment for ≥ 1 month&#xD;
&#xD;
          3. No systemic corticosteroid treatment 4 weeks before the enrollment&#xD;
&#xD;
        Group of NAFLD (inclusion criteria)&#xD;
&#xD;
          1. Ultrasound criteria of non-alcoholic fatty liver disease or&#xD;
&#xD;
          2. Confirmed non-alcoholic fatty liver disease using FibroMax test&#xD;
&#xD;
        Control group inclusion criteria&#xD;
&#xD;
          1. Men and women aged ≥ 18 and &lt;80 years&#xD;
&#xD;
          2. Signed informed consent form&#xD;
&#xD;
        Control group for arterial hypertension (inclusion criteria):&#xD;
&#xD;
        1. No history of cardiovascular diseases, COPD or asthma&#xD;
&#xD;
        Control group for COPD and asthma (inclusion criteria):&#xD;
&#xD;
        1. No history of diabetes mellitus, NAFLD, COPD and asthma&#xD;
&#xD;
        Exclusion criteria for all groups&#xD;
&#xD;
          1. Age &lt; 18 years and ≥80 years&#xD;
&#xD;
          2. Denial of further participation&#xD;
&#xD;
          3. Obesity with BMI≥40 kg/m2&#xD;
&#xD;
          4. History of organ transplantion&#xD;
&#xD;
          5. Psychiatric disorder, limiting participation in the study&#xD;
&#xD;
          6. Acute infections&#xD;
&#xD;
          7. Exacerbation of chronic infection 2 weeks before the enrollment&#xD;
&#xD;
          8. Cancer with no radical treatment&#xD;
&#xD;
          9. Pregnancy and lactation&#xD;
&#xD;
         10. Alcohol and drug addition&#xD;
&#xD;
         11. Chronic kidney disease with GFR &lt;30 ml/min/1.73m2&#xD;
&#xD;
         12. Systemic autoimmune diseases&#xD;
&#xD;
         13. Inflammatory bowel disease&#xD;
&#xD;
         14. Antimicrobial and probiotic treatment 3 months before the enrollment&#xD;
&#xD;
        Additional exclusion criteria adjusted for each group&#xD;
&#xD;
        Group of arterial hypertension (exclusion criteria):&#xD;
&#xD;
          1. Ischemic heart disease (angina pectoris, myocardial infarction), cerebrovascular&#xD;
             disease (stroke, transient ischemic attack), occlusive peripheral arterial disease,&#xD;
             revascularization of any vascular bed.&#xD;
&#xD;
          2. Cardiomyopathies&#xD;
&#xD;
          3. Symptomatic arterial hypertension&#xD;
&#xD;
          4. Diabetes mellitus&#xD;
&#xD;
          5. Signs of previous myocardial infarction on ECG&#xD;
&#xD;
          6. Arrhythmias (parohysmal arrhythmias, atrial fibrillation, sinoatrial block,&#xD;
             atrioventricular block grade II-III)&#xD;
&#xD;
          7. Signs of current myocardial ischemia on ECG&#xD;
&#xD;
          8. Decompensated heart failure&#xD;
&#xD;
        Group of COPD and asthma (exclusion criteria):&#xD;
&#xD;
          1. Exacerbation of COPD or asthma 3 months before the enrollment which required&#xD;
             antibiotic treatment or systemic corticosteroids.&#xD;
&#xD;
             Group of type 2 diabetes mellitus (exclusion criteria):&#xD;
&#xD;
          2. Type 1 diabetes mellitus and other specific types of diabetes&#xD;
&#xD;
          3. Severe microangiopathy: proliferative and terminal stage of diabetic retinopathy,&#xD;
             chronic kidney disease (GFR &lt; 30 ml/min/1,73 m2) for patients with type 2 diabetes&#xD;
&#xD;
          4. The history of moderate, severe and very severe COPD&#xD;
&#xD;
          5. The history of moderate or severe asthma&#xD;
&#xD;
          6. Vegetarians or vegans&#xD;
&#xD;
        Group of non-alcoholic fatty liver disease (exclusion criteria):&#xD;
&#xD;
          1. Chronic liver diseases except NAFLD&#xD;
&#xD;
          2. The history of moderate, severe and very severe COPD&#xD;
&#xD;
          3. The history of moderate or severe asthma&#xD;
&#xD;
          4. Vegetarians or vegans&#xD;
&#xD;
          5. Diabetes mellitus&#xD;
&#xD;
        Criteria for groups of heart failure and obstructive atherosclerosis (retrospective)&#xD;
&#xD;
        Inclusion criteria for HF-pEF group:&#xD;
&#xD;
          1. Men and women aged ≥ 18 and &lt;80 years&#xD;
&#xD;
          2. Signs and symptoms of heart failure&#xD;
&#xD;
          3. Left ventricular diastolic dysfunction&#xD;
&#xD;
          4. Left ventricular ejection fraction ≥50%&#xD;
&#xD;
          5. NT-pro BNP &gt;125 pg/ml&#xD;
&#xD;
          6. Signed study informed consent form&#xD;
&#xD;
        Inclusion criteria for HF-rEF group:&#xD;
&#xD;
          1. Men and women aged ≥ 35 and &lt;80 years&#xD;
&#xD;
          2. Signs and symptoms of heart failure&#xD;
&#xD;
          3. Left ventricular ejection fraction &lt;50%&#xD;
&#xD;
          4. Signed study informed consent form&#xD;
&#xD;
        Inclusion criteria for obstructive atherosclerosis group:&#xD;
&#xD;
          1. Men and women aged ≥ 35 and &lt;80 years&#xD;
&#xD;
          2. Symptoms and signs of obstructive atherosclerosis of any vascular bed:&#xD;
&#xD;
               1. Ischemic heart disease or&#xD;
&#xD;
               2. Revascularization of coronary, renal, brachiocephalic or lower extremity arteries&#xD;
                  or&#xD;
&#xD;
               3. carotid endarterectomy or&#xD;
&#xD;
               4. chronic lower extremity ischemia or&#xD;
&#xD;
               5. history of myocardial infarction, stroke, transient ischemic attack or&#xD;
&#xD;
               6. renovascular AH&#xD;
&#xD;
               7. atherosclerotic aorta aneurysm&#xD;
&#xD;
          3. Signed study informed consent form&#xD;
&#xD;
        Inclusion criteria for control group for HF-pEF, HF-rEF and obstructive atherosclerosis&#xD;
&#xD;
          1. Men and women aged ≥ 18 and &lt;80 years.&#xD;
&#xD;
          2. No signs or symptoms of chronic heart failure&#xD;
&#xD;
          3. No signs of left ventricular diastolic dysfunction&#xD;
&#xD;
          4. No history, signs or symptoms of obstructive atherosclerosis of any vascular bed&#xD;
&#xD;
          5. Signed study informed consent form&#xD;
&#xD;
        Exclusion criteria for groups with HF-pEF, HF-rEF and obstructive atherosclerosis:&#xD;
&#xD;
          1. Age &lt;18 and ≥80 years.&#xD;
&#xD;
          2. Refuse to sign study informed consent form&#xD;
&#xD;
          3. Body mass index ≥35 kg/m2&#xD;
&#xD;
          4. Chronic kidney disease with GFR &lt;30 ml/min/1,73 m2&#xD;
&#xD;
          5. Current smoking&#xD;
&#xD;
          6. Moderate or severe COPD&#xD;
&#xD;
          7. Moderate or severe asthma&#xD;
&#xD;
          8. Acute infections or exacerbation of chronic infections 2 weeks prior to study&#xD;
             enrollment&#xD;
&#xD;
          9. History of allergic reactions to gadolinium contrast&#xD;
&#xD;
         10. Hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy:&#xD;
             primary, amyloidosis, glycogen storage diseases, hemochromatosis, sarcoidosis, drug&#xD;
             induced cardiomyopathy, radiation heart disease, constrictive pericarditis).&#xD;
&#xD;
         11. Connective tissue disease&#xD;
&#xD;
         12. Cancer with no radical treatment&#xD;
&#xD;
         13. Pregnancy or lactation&#xD;
&#xD;
         14. Inflammatory bowel disease&#xD;
&#xD;
         15. Use of antimicrobial agents, probiotics or systemic corticosteroids 3 months before&#xD;
             the enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Healthcare of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>101990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Strategic Planning and Management of Biomedical Health Risks of the Federal Medical Biological Agency</name>
      <address>
        <city>Moscow</city>
        <zip>119121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Medical Research Center for Therapy and Preventive Medicine</investigator_affiliation>
    <investigator_full_name>Anastasia Kaburova</investigator_full_name>
    <investigator_title>junior researcher</investigator_title>
  </responsible_party>
  <keyword>chronic noncommunicable diseases</keyword>
  <keyword>gut permeability</keyword>
  <keyword>inflammation</keyword>
  <keyword>gut microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Noncommunicable Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

